Biotechnology in Cuba: 20 years of scientific, social and economic progress

Journal of Commercial Biotechnology

Volumn 13, Issue 1, 2006, Pages 1-11

  López Mola, Ernesto ^a   Silva, Ricardo ^a   Acevedo, Boris ^a   Buxadó, José A ^a   Aguilera, Angel ^a   Herrera, Luis ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FOREIGN ECONOMIC PRESSURES;

DEVELOPING COUNTRIES; ECONOMIC AND SOCIAL EFFECTS; PRODUCT DEVELOPMENT;

BIOTECHNOLOGY;

ANTINEOPLASTIC AGENT; CANCER VACCINE; CIGB 300; CITOPROT P; DENGUE VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; RECOMBINANT ENZYME; RECOMBINANT STREPTOKINASE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; WOUND HEALING PROMOTING AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTECHNOLOGY; CARCINOMA IN SITU; CLINICAL TRIAL; COST CONTROL; CUBA; DEVELOPING COUNTRY; DIABETIC FOOT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ECONOMIC DEVELOPMENT; FOOD BIOTECHNOLOGY; GENETIC ENGINEERING; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INTERNATIONAL COOPERATION; INTRACARDIAC THROMBOSIS; INVESTMENT; MEDICAL RESEARCH; NONHUMAN; PATENT; PLANT BIOTECHNOLOGY; SURGICAL EQUIPMENT; UTERINE CERVIX CARCINOMA IN SITU; VACCINE PRODUCTION;

EID: 34447281325     PISSN: 14628732     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jcb.3050038     Document Type: Article

References (24)

1. United Nations Development Programme. (2001). Human development report 2001: Making new technologies work for human development', Oxford University Press, Oxford, UK.
2. Mola, E.L., Acevedo, B.E., Rodríguez, R.S., Tormo, B., Montero, R. & Martínez, L.H. (2003). Development of Cuban biotechnology. J. Comm. Biotechnol. 9(2), 147-152.
3. Kaiser, J. (1998). Cuba's billion-dollar biotech gamble. Science. 282(5394), 1626-1628.
4. Thorsteinsdóttir, H., Sáenz, T.W., Quach, U., Daar, A. S. & Singer, P. A. (2004). Cuba-innovation through synergy. Nat. Biotechnol. 22(Supp), DC 19-DC24.
5. Carol, F. (2004). Cuban biotech advances in a range of diverse areas. Gen. Eng. News 24(12), 1.
6. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. J. (2003). The price of innovation: New estimates of drug development costs. J. Health Econ. 22, 151-185.
7. Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Schumock, G. T., Grim, P., Hunkler, R. J. & Hontz, K. M. (2006). Projecting future drug expenditures - 2006. Am. J. Health Syst. Pharm. 63(2), 123-138.
8. Giles, J. (2005).V¿ive la revolución? Nature 436, 322-324.
9. Murray, M. (2006. Cubans developing therapy for diabetic ulcers, NBC News. http://msnbc.msn.com/id/10777359/ (accessed 3rd October, 2006).
10. Perea, S.E., Reyes,O., Puchades, Y., Mendoza, O., Vispo, N.S., Torrens, I., Santos, A., Silva, R., Acevedo, B., López, E., Falcon, V. & Alonso, D.F. (2004. Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res. 64 (19), 7127-7129.
11. World Health Organization. (1996). Hepatitis B vaccine: Universal Immunization Policy 1996. Expanded Program on Immunization (EPI). 1211 Geneva 27, Switzerland.
12. Vérez-Bencomo, V., Fernández-Santana, V., Hardy, E., Toledo, M.E., Rodríguez, M.C., Heynngnezz, L., Rodríguez, A., Baly, A., Herrera, L., Izquieredo, M., Villar, A., Valdés, Y., Cosme, K., Deler, M.L., Montané, M., Garcia, E., Ramos, A., Aguilar, A., Medina, E., Toraño, G., Sosa, I., Hernández, I., Martínez, R., Muzachio, A., Carmenates, A., Costa, L., Cardoso, F., Campa, C., Diaz, M. & Roy, R. (2004). A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305 (5683), 522-525.
13. Milstien, J., Munira, S. L. & McKinney, S. L. (2003). Issues in selection of DTwP-based combination vaccines. Vaccine. 21 15), 1658-1664.
14. Gonzalez, G., Crombet, T., Catala, M., Mirabal, V., Hernández, J.C., Gonzalez, Y., Marinello, P., Guillén, G. & Lage, A. (1998). A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial. Ann. Oncol. 9 (4), 431-435.
15. Carmenate, T., Canaan, L., Alvarez, A., Delgado, M., González, S., Menéndez, T., Rodes, L. & Guillén, G. (2004). Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates. FEMS Immunol. Med. Microbiol. 40 (3, 193-199.
16. Pérez, A., Dickinson, F., Cinza, Z., Ruiz, A., Serrano, T., Sosa, J., González, S., Gutierrez, Y., Nazabal, C., Gutierrez, O., Guzmán, D., Díaz, M., Delgado, M., Caballero, E., Sardinas, G., Alvarez, A., Martín, A., Guillén, G. & Silva, R. (2001). Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers. Biotechnol. Appl. Biochem 34 (2), 121-125.
17. Falcón, V., Acosta-Rivero, N., Shibayama, M., Chinea, G., Gavilondo, J.V., de la Rosa, M.C., Menéndez, I., Gra, B., Dueñas-Carrera, S., Vina, A., Garcia, W., González-Bravo, M., Luna-Muñoz, J., Miranda-Sánchez, M., Morales-Grillo, J., Kouri, J. & Tsutsumi, V. (2005). HCV core protein localizes in the nuclei of nonparenchymal liver cells from chronically HCV-infected patients. Biochem. Biophys. Res. Commun. 329(4), 1320-1328.
18. Rodríguez, R., Chinea, G., López, N., Pons, T. & Vriend, G. (1998). Homology modeling, model and software evaluation: Three related resources. Bioinformatics.14(6), 523-528.
19. Besada, V., Diaz, M., Becker, M., Ramos, Y., Castellanos-Serra, L. & Fichtner, I. (2006). Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance. Proteomics. 6(3), 1038-1048.
20. Dueñas, M. & Borrebaeck, C.A. (1994). Clonal selection and amplification of phage displayed antibodies by linking antigen recognition and phage replication. Biotechnology. 12 (10), 999-1002.
21. Science Citation Index. (http://www.isinet.com).
22. Betancourt, B.Y., Marrero-Miragaya, M.A., Jiménez-López, G., Valenzuela-Silva, C., Garcia-Iglesias, E., Hernández-Bernal, F., Debesa-Garcia, F., González-López, T., Alvarez-Falcón, L. & López-Saura, P.A. (2005). Cubanf National Network of Pharmacoepidemiology. Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction. BMC Clin Pharmacol. 5, 5.
23. Kaiser, J. (2004). Synthetic vaccine is a sweet victory for Cuban science. Science. 305 (5683), 460.
24. Rodríguez, M., Ramírez, N.I., Ayala, M., Freyre, F., Pérez, L., Triguero, A., Mateo, C., Selman-Housein, G., Gavilondo, J.V. & Pujol, M. (2005). Transient expression in tobacco leaves of an aglycosylated recombinant antibody against the epidermal growth factor receptor. Biotechnol. Bioeng. 89(2), 188-194.